Literature DB >> 8381505

Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system.

P Follesa1, I Mocchetti.   

Abstract

Basic fibroblast growth factor (bFGF) and nerve growth factor (NGF) are two neurotrophic factors that play a role in neuronal maintenance and repair. The identification and characterization of mechanisms regulating neurotrophic factor availability in the central nervous system are vital to the development of therapeutic tools for prevention of neuronal degeneration. The lipophilic beta-adrenergic receptor (BAR) agonist clenbuterol was used to assess whether activation of central BAR changes the levels of NGF and bFGF mRNA. Within 5 hr, clenbuterol (10 mg/kg, intraperitoneally) elicited a 2-3-fold increase in bFGF and NGF mRNA content in rat cerebral cortex. The induction of bFGF and NGF mRNA expression showed anatomical specificity. Among the various brain areas examined, bFGF mRNA levels were increased in the cerebral cortex, hippocampus, and cerebellum, whereas induction of NGF mRNA was observed only in the cerebral cortex. Isoproterenol, a BAR agonist that does not cross the blood-brain barrier, also elicited a 2-3-fold increase in bFGF and NGF mRNA in the cerebral cortex. Propranolol (5 mg/kg, intraperitoneally), a lipophilic BAR antagonist, blocked the induction of NGF and bFGF mRNA mediated by either isoproterenol or clenbuterol, whereas nadolol (5 mg/kg, intraperitoneally), a BAR antagonist that does not cross the blood-brain barrier, blocked only the effect of isoproterenol. Therefore, activation of both central and peripheral BAR play a role in the regulation of bFGF and NGF mRNA expression. Moreover, in adrenalectomized rats, isoproterenol failed to increase bFGF and NGF mRNA, whereas clenbuterol elicited a 2-fold increase in bFGF mRNA in the cortex and hippocampus. Our data suggest that both adrenal steroids and noradrenaline might regulate the availability of selective neurotrophic factors in the adult central nervous system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381505

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  beta-adrenergic receptor-induced activation of nerve growth factor gene transcription in rat cerebral cortex involves CCAAT/enhancer-binding protein delta.

Authors:  A M Colangelo; P F Johnson; I Mocchetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

2.  Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage.

Authors:  R Wen; T Cheng; Y Li; W Cao; R H Steinberg
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

3.  Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor.

Authors:  Ru-Quan Han; Yi-Bing Ouyang; Lijun Xu; Rani Agrawal; Andrew J Patterson; Rona G Giffard
Journal:  Anesth Analg       Date:  2009-01       Impact factor: 5.108

4.  Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.

Authors:  Ling Zhang; Hua-Ming Mai; Jing Zheng; Jia-Wei Zheng; Yan-An Wang; Zhong-Ping Qin; Ke-Lei Li
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 5.  The connections of Locus Coeruleus with hypothalamus: potential involvement in Alzheimer's disease.

Authors:  Alessandro Galgani; Filippo Sean Giorgi; Stefano Puglisi-Allegra; Carla Letizia Busceti; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2021-05-03       Impact factor: 3.575

Review 6.  Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.

Authors:  Lynda Peterson; Kathleen P Ismond; Elisha Chapman; Patrick Flood
Journal:  J Immunol Res       Date:  2014-01-19       Impact factor: 4.818

Review 7.  The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer's Disease.

Authors:  Filippo S Giorgi; Larisa Ryskalin; Riccardo Ruffoli; Francesca Biagioni; Fiona Limanaqi; Michela Ferrucci; Carla L Busceti; Ubaldo Bonuccelli; Francesco Fornai
Journal:  Front Neuroanat       Date:  2017-09-19       Impact factor: 3.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.